Ruboxistaurin shows favorable effects in type 2 diabetes and diabetic nephropathy


A one-year pilot study examined the effect of Ruboxistaurin ( Arxxant ) in patients with type 2 diabetes and diabetic nephropathy.

Data showed that in patients being treated with angiotensin converting enzyme inhibitors ( ACE inhibitors ), angiotensin receptor blockers ( ARBs ), or both, Ruboxistaurin significantly reduced albuminuria, an indicator of diabetic kidney damage, by 24%, compared to a non-significant 9% reduction in patients taking placebo.

" The results from this study are very encouraging for people with type 2 diabetes who suffer from diabetic nephropathy," said Katherine R. Tuttle, lead investigator of the study, from Providence Medical Research Center and The Heart Institute of Spokane. " The significant improvement of albuminuria with Ruboxistaurin in patients already treated with ACE inhibitors or ARBs suggests that the drug may be helpful in further slowing the progression of kidney disease."

Albuminuria is considered the first clinical indication of diabetic nephropathy. Diabetic nephropathy is a diabetic microvascular complication ( DMC ) caused by damage to the small blood vessels in the kidneys. It occurs in approximately 40 percent of people with diabetes and is the leading cause of kidney failure in the United States and the developed world.

Reductions in albuminuria with Ruboxistaurin were seen after one month of treatment and remained consistent throughout the study. In addition, patients taking placebo experienced a significant loss of kidney function after 1 year, however kidney function was stable in patients treated with Ruboxistaurin.

In this multicenter, randomized, double-blinded, parallel placebo- controlled trial, 123 subjects were randomized at 17 clinical sites in the United States to receive either 32 mg/day of Ruboxistaurin or placebo. Participants were required to be taking stable doses of either ACE inhibitors, ARBs, or both, for 6 months prior to the study and these agents were continued throughout the trial. Baseline characteristics did not differ significantly between treatment groups. Blood glucose and blood pressure control was similar at the beginning and throughout the study.

Analyses of adverse events in this trial revealed no significant differences between the Ruboxistaurin ( 15 reported ) and placebo ( 9 reported ) groups, except in the placebo group for episodes of hypertension requiring intervention ( 8% of placebo participants had an episode of hypertension requiring intervention compared with 0% in Ruboxistaurin treated group ).
The most frequently reported adverse event in this clinical trial was hypertension. Three Ruboxistaurin-treated participants withdrew due to adverse events ( decreased libido, impaired mental status, and metastatic cancer ).
Based upon the results of this pilot study, Ruboxistaurin was well tolerated; but the small sample size and limited duration of follow-up precludes a firm conclusion about safety.

Ruboxistaurin is a specific protein kinase C beta ( PKC b ) inhibitor, the first of a new class of compounds being investigated for the treatment of diabetic peripheral neuropathy, diabetic retinopathy and diabetic nephropathy, the three major diabetic microvascular complications ( DMCs ) associated with type 1 and type 2 diabetes. Metabolic factors associated with diabetes often lead to damage to the small blood vessels in the nerves, eyes and kidneys, ultimately leading to DMCs.

Pre-clinical data show that Ruboxistaurin is a specific inhibitor of PKC b.
PKC b is an enzyme that has been implicated in the underlying process of microvascular damage caused by diabetes.

Source: American Diabetes Association ( ADA ) 65th Annual Scientific Sessions, 2005


XagenaMedicine_2005



Indietro

Altri articoli

The FDA ( US Food and Drug Administration ) has approved the following expanded indication for Entresto ( Sacubitril /...


SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...


Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...


The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...


Angiotensin converting enzyme inhibitors ( ACE inhibitors ) and angiotensin receptor blockers ( ARBs; sartans ) are widely prescribed for...